Kuano

United Kingdom - London

• 13/09/2023
• Seed
• $2,247,000

Our discovery platform uniquely combines target quantum mapping and AI led chemistry to enable faster development of better drug candidates. Our unique approach tackles common challenges in both AI driven drug design and target driven drug discovery.

Quantum Mapping of targets introduces selectivity from the start, producing superior candidates in fewer design rounds. Identifying better starting points for AI-led chemistry eliminates bottlenecks in the hit to candidate optimization phase. Generating better Enzyme Inhibitors by targeting Quantum Transition States. We work with enzyme inhibitors in a unique way, continually developing tools to address the challenges of working with machine learning and quantum simulations in drug discovery. This strategy significantly improves the quality of new drugs being produced, as well as reduces discovery time.

Our advisors and partners include leading academics and providers in the fields of quantum computing, AI and machine learning and drug discovery. In addition to our in-house discovery programs, we are interested in drug discovery collaborations with pharmaceutical and biotech companies seeking new approaches to novel, first in class, best in class or next generation inhibitors for validated or intractable enzyme targets.

Related People

Vid StojevicCo Founder

United Kingdom - Cambridge, England

Specialties: theoretical physics, many-body quantum physics, tensor networks, string theory, machine learning, mathematical modelling, data analysis and programming

LinkedIn https://www.linkedin.com/in/vid-stojevic-32640314/